Pharma Company Share Price Surges Over 2.5% After U.S. FDA Inspection Update
Join Us
Follow Us
The stock has gained 66.36 per cent from its 52-week low of Rs 1,016.10 per share.
✨ Key Takeaways
On Monday, shares of Aurobindo Pharma jumped 2.74 per cent to Rs 1,690.40 per share from its previous closing of Rs 1,645.30 per share. As of 12:08 IST, the stock had touched an Intraday high of Rs 1,694.90, representing a 3.01 per cent surge from the previous close. The stock’s 52-week high is Rs 1,694.90 per share and its 52-week low is Rs 1,016.10 per share.
The gains came after Aurobindo Pharma reported that the U.S. Food and Drug Administration (U.S. FDA) had completed a routine inspection of Unit-VI, an active pharmaceutical ingredient (API) manufacturing facility operated by Apitoria Pharma, a wholly owned subsidiary of Aurobindo Pharma. The facility is located in E-Bonangi Village, Parawada Mandal, Anakapalli district, Andhra Pradesh. The inspection was conducted from August 24 to August 28, 2026.
The inspection concluded with three observations, which the company described as procedural in nature. Aurobindo Pharma said it will respond to the U.S. FDA within the stipulated timeline. The observations are related to procedures rather than indicating a product quality or safety issue, according to the company.
The latest inspection follows other recent U.S. FDA observations across the Aurobindo Pharma group. Lannett Company LLC, a wholly owned step-down subsidiary located in Seymour, Indiana, received four procedural observations after a routine inspection conducted from August 17 to August 21, 2026. Separately, AuroPeptides, the group's Telangana-based peptide API manufacturing arm, received one observation related to facility and equipment maintenance.
Also Read - Defence Company Share Price Jumps Nearly 3% After Securing Rs 117.88 Crore DRDO Order
Despite the regulatory developments, Aurobindo Pharma has reported strong financial performance. For the June quarter of FY27, the company reported consolidated revenue of Rs 9,150.3 crore, marking a 16.3 per cent year-on-year increase. Consolidated net profit rose 25.2 per cent year-on-year to Rs 1,032 crore.
The stock has also maintained strong momentum over the past year. Aurobindo Pharma's shares have gained 64.45 per cent over the last one year and are currently trading at their 52-week high of Rs 1,694.90 per share.
The company has a market cap of over Rs 300 crore. The stock price has surged over 64.45 per cent in the last 1 year.
The stock has gained 66.36 per cent from its 52-week low of Rs 1,016.10 per share.
Disclaimer: The article is for informational purposes only and not investment advice.
What do you think about Aurobindo Pharma's latest U.S. FDA inspection outcome and the stock's strong momentum? Share your views in the comments below.